198 related articles for article (PubMed ID: 12538800)
21. Effects of entacapone and tolcapone on mitochondrial membrane potential.
Haasio K; Koponen A; Penttilä KE; Nissinen E
Eur J Pharmacol; 2002 Oct; 453(1):21-6. PubMed ID: 12393055
[TBL] [Abstract][Full Text] [Related]
22. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
[TBL] [Abstract][Full Text] [Related]
23. Extending levodopa action: COMT inhibition.
Martínez-Martín P; O'Brien CF
Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
[TBL] [Abstract][Full Text] [Related]
24. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.
Detrait ER; Carr GV; Weinberger DR; Lamberty Y
Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286
[TBL] [Abstract][Full Text] [Related]
25. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.
Haasio K; Nissinen E; Sopanen L; Heinonen EH
J Neural Transm (Vienna); 2002 Nov; 109(11):1391-401. PubMed ID: 12454735
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases.
Lv X; Wang XX; Hou J; Fang ZZ; Wu JJ; Cao YF; Liu SW; Ge GB; Yang L
Toxicol Appl Pharmacol; 2016 Jun; 301():42-9. PubMed ID: 27089846
[TBL] [Abstract][Full Text] [Related]
27. The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats.
Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
J Pharm Pharmacol; 1994 Jul; 46(7):571-4. PubMed ID: 7996385
[TBL] [Abstract][Full Text] [Related]
28. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase.
Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P
J Pharmacol Exp Ther; 1997 Aug; 282(2):812-7. PubMed ID: 9262345
[TBL] [Abstract][Full Text] [Related]
29. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.
Grünig D; Felser A; Bouitbir J; Krähenbühl S
Toxicol In Vitro; 2017 Aug; 42():337-347. PubMed ID: 28526448
[TBL] [Abstract][Full Text] [Related]
30. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
[TBL] [Abstract][Full Text] [Related]
31. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
Törnwall M; Tuomainen P; Männistö PT
Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912
[TBL] [Abstract][Full Text] [Related]
32. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
Vieira-Coelho MA; Gomes P; Serrão MP; Soares-da-Silva P
Kidney Int; 2001 May; 59(5):1683-94. PubMed ID: 11318939
[TBL] [Abstract][Full Text] [Related]
33. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
Vieira-Coelho MA; Soares-da-Silva P
Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
[TBL] [Abstract][Full Text] [Related]
34. Practical issues with COMT inhibitors in Parkinson's disease.
Waters C
Neurology; 2000; 55(11 Suppl 4):S57-9; discussion S60-4. PubMed ID: 11147511
[TBL] [Abstract][Full Text] [Related]
35. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats.
Khromova I; Voronina T; Kraineva VA; Zolotov N; Männistö PT
Behav Brain Res; 1997 Jun; 86(1):49-57. PubMed ID: 9105581
[TBL] [Abstract][Full Text] [Related]
36. COMT inhibitors and liver toxicity.
Watkins P
Neurology; 2000; 55(11 Suppl 4):S51-2; discussion S53-6. PubMed ID: 11147510
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.
Keränen T; Gordin A; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Schultz E; Seppälä L; Wikberg T
Eur J Clin Pharmacol; 1994; 46(2):151-7. PubMed ID: 8039535
[TBL] [Abstract][Full Text] [Related]
38. Issues important for rational COMT inhibition.
Dingemanse J
Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
40. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Marin C; Aguilar E; Bonastre M; Tolosa E; Obeso JA
Exp Neurol; 2005 Mar; 192(1):184-93. PubMed ID: 15698633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
